Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomised trial

Topical Steroids ◽

Phase 3

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

10.1016/j.jaad.2020.06.198 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB28

Author(s):

Peter Lio ◽

Audrey Nosbaum ◽

Tracy Cardillo ◽

Amy DeLozier ◽

Margaret Gamalo ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Inadequate Response ◽

Phase 3 ◽

Skin Symptoms ◽

Patient Reported

26053 Improvement in sleep is associated with improved quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a phase 3 trial of baricitinib therapy

10.1016/j.jaad.2021.06.080 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB14

Author(s):

Peter Lio ◽

George Han ◽

Edward Lain ◽

Catherine Maari ◽

Susan Ball ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy

Journal of Dermatological Treatment ◽

10.1080/09546634.2021.1914308 ◽

2021 ◽

pp. 1-6

Author(s):

Peter A. Lio ◽

Eric L. Simpson ◽

George Han ◽

Jennifer Soung ◽

Susan Ball ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3

Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dermatology and Therapy ◽

10.1007/s13555-017-0181-6 ◽

2017 ◽

Vol 7 (2) ◽

pp. 243-248 ◽

Cited By ~ 19

Author(s):

Eric L. Simpson

Keyword(s):

Quality Of Life ◽

Clinical Trials ◽

Atopic Dermatitis ◽

Health Related Quality ◽

Phase 3 ◽

Randomized Controlled ◽

Related Quality ◽

Health Related

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial

British Journal of Dermatology ◽

10.1111/bjd.15905 ◽

2018 ◽

Vol 178 (2) ◽

pp. 406-414 ◽

Cited By ~ 22

Author(s):

A. Tsianakas ◽

T.A. Luger ◽

A. Radin

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Controlled Clinical Trial ◽

Severe Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial

British Journal of Dermatology ◽

10.1111/bjd.16293 ◽

2018 ◽

Vol 178 (2) ◽

pp. e168-e168 ◽

Cited By ~ 1

Author(s):

A. Tsianakas ◽

T.A. Luger ◽

A. Radin

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Atopic Dermatitis ◽

Adult Patients ◽

Controlled Clinical Trial ◽

Severe Atopic Dermatitis

15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

10.1016/j.jaad.2020.06.252 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB41

Author(s):

Gil Yosipovitch ◽

Thomas Bieber ◽

Linda Stein Gold ◽

Shawn Kwatra ◽

Svitlana Tatulych ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Atopic Dermatitis ◽

Severity Index ◽

Phase 3

Faculty Opinions recommendation of Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976556.793472766 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

International Collaboration ◽

Ovarian Neoplasms ◽

Randomised Trial ◽

Advanced Ovarian Cancer ◽

Life Outcomes ◽

Standard Chemotherapy ◽

Phase 3

Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study

Journal of Drugs in Dermatology ◽

10.36849/jdd.2020.5422 ◽

2020 ◽

Vol 19 (10) ◽

pp. 943-948

Author(s):

Peter Lio ◽

Andreas Wollenberg ◽

Jacob Thyssen ◽

Evangeline Pierce ◽

Maria Rueda ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Real World ◽

Adult Patients ◽

Lesion Location